NAPOLI-1 Phase 3 study confirms benefit for ONIVYDE regimen for pancreatic cancer

Merrimack Pharmaceuticals has announced the final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin to treat metastatic pancreatic canc …

Source: Drug Development Technology - October 11, 2016 Category: Pharmaceuticals Source Type: news